PHIO PHARMACEUTICALS CORP. Derivative Liability, Fair Value, Gross Liability
PHIO PHARMACEUTICALS CORP. (PHIO) had Derivative Liability, Fair Value, Gross Liability of $8.72 million as of 2011-09-24, per its 10-K filed 2013-03-29.
Discontinued › Notes
us-gaap:DerivativeFairValueOfDerivativeLiability · last filed 2013-03-29
- 2011-09-24: Derivative Liability, Fair Value, Gross Liability $8.72M.
| Period end | Derivative Liability, Fair Value, Gross Liability |
|---|---|
| 2011-09-24 | $8.72M 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |